Prostate cancer remains a significant health concern for men in Germany, with approximately 65,000 new cases diagnosed annually and ranking as the second leading cause of cancer-related deaths. While early detection offers a strong chance of successful treatment, the disease can become far more challenging to manage as it progresses. Now, researchers are exploring a new avenue for improved diagnosis and treatment planning: a blood test that could predict the aggressiveness of the cancer.
A team of scientists at the OncoRay – National Center for Radiation Research in Oncology in Dresden has identified a protein, MMP11 (Matrix-Metalloproteinase 11), as a potential biomarker for aggressive prostate cancer. This discovery, published in 2025, opens the door to a less invasive method of assessing a patient’s prognosis and tailoring treatment strategies. The research builds on previous work demonstrating the potential of specific genes as biomarkers for the disease.
Identifying a Key Biomarker: MMP11
The research, led by Professor Anna Dubrovska, focused on understanding the molecular mechanisms driving prostate cancer progression. Dubrovska’s team investigated the role of Aldehyde Dehydrogenases (ALDH), enzymes crucial for human metabolism. Previous studies had indicated that ALDH genes influence the survival of tumor cells in the bloodstream and their ability to metastasize, impacting resistance to radiation therapy and the formation of bone metastases. This led them to explore the connection between ALDH, and MMP11.
Dr. Ielizaveta Gorodetska, a key researcher on the project, detailed the underlying ALDH1A1/MMP11 signaling pathway. The team found that ALDH proteins regulate a signaling protein called Transforming Growth Factor Beta 1 (TGFβ1). TGFβ1, in turn, controls the production of proteins, including MMP11. This cascade contributes significantly to the increased aggressiveness and invasiveness of tumor cells. Analysis of patient data revealed a strong correlation between high MMP11 gene expression and advanced, high-risk prostate cancer. Further validation through direct measurement of MMP11 protein levels in patient blood plasma confirmed these findings.
Potential for a Minimally Invasive Blood Test
Elevated MMP11 concentrations in the blood were found to be a potential indicator of metastasis and a less favorable prognosis for patients with metastatic prostate cancer undergoing local radiation therapy. This suggests the possibility of a minimally invasive blood test that could identify aggressive disease early, inform treatment decisions, and monitor treatment effectiveness in real-time. “Our data show that MMP11 is not only a biologically relevant driver of tumor aggressiveness but also could be a clinically useful marker,” explained Dubrovska. “Long-term, such a blood test could help to treat patients more individually and avoid over- or undertreatment.”
The development of a clinically viable test is expected to take several years, mirroring the timeline for other biomarker-based tests. However, the current findings represent a significant step forward in personalized oncology. Researchers are already collaborating with the Maria Sklodowska-Curie National Research Institute of Oncology in Poland to validate the MMP11 biomarker in larger, independent patient cohorts from Germany and Poland. This collaborative effort is supported by funding from the German Research Foundation.
According to data from the Robert Koch Institute, approximately 80,000 new cases of prostate cancer were diagnosed in Germany in 2023. This new research offers a potential tool to refine treatment strategies for this prevalent disease.
The next steps involve further validation of the MMP11 biomarker and the development of a standardized, reliable blood test. While challenges remain, this research offers a promising path toward more precise, personalized, and patient-centered approaches to diagnosing and treating prostate cancer.
What are your thoughts on the potential of blood-based biomarkers in cancer treatment? Share your comments below, and please share this article with anyone who might find it informative.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
